Doximity Inc experienced a price increase of 5.01% during regular trading, crossing above its 5-day SMA. This movement comes amid broad market strength, with the Nasdaq-100 up 0.91% and the S&P 500 up 0.80%. The stock's rise indicates positive investor sentiment and aligns with the overall market trend.
The surge is attributed to broad market strength, which has positively influenced many stocks in the sector. The favorable conditions in the market have allowed Doximity to gain traction, reflecting a broader trend of investor confidence in technology and healthcare stocks.
As Doximity continues to perform well, investors may look for further developments in the company’s strategic initiatives and market positioning. The current momentum could lead to increased interest from institutional investors, potentially driving the stock higher in the near term.
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 62.75 USD with a low forecast of 50.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 62.75 USD with a low forecast of 50.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
4 Hold
1 Sell
Moderate Buy
Current: 38.730
Low
50.00
Averages
62.75
High
82.00
Current: 38.730
Low
50.00
Averages
62.75
High
82.00
Wells Fargo
Stan Berenshteyn
Equal Weight -> Overweight
upgrade
$65 -> $55
2026-01-20
Reason
Wells Fargo
Stan Berenshteyn
Price Target
$65 -> $55
AI Analysis
2026-01-20
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo analyst Stan Berenshteyn upgraded Doximity to Overweight from Equal Weight with a price target of $55, down from $65. The firm views investor concerns as overdone after its survey indicated Doximity has "sufficient differentiation." While low visibility and completive concerns have been pressuring the shares, Wells' survey supports "platform staying power" for Doximity, the analyst tells investors in a research note. The firm believes the shares can move higher without a pickup in revenue growth.
Goldman Sachs
David Roman
Sell -> Neutral
upgrade
$62 -> $49
2026-01-09
Reason
Goldman Sachs
David Roman
Price Target
$62 -> $49
2026-01-09
upgrade
Sell -> Neutral
Reason
Goldman Sachs analyst David Roman upgraded Doximity to Neutral from Sell with a price target of $49, down from $62. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note. The firm sees valuation re-based and consensus numbers more accurately capturing the Doximity's forward outlook.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DOCS
Unlock Now
Canaccord
Richard Close
Hold
downgrade
$58 -> $48
2026-01-08
Reason
Canaccord
Richard Close
Price Target
$58 -> $48
2026-01-08
downgrade
Hold
Reason
Canaccord analyst Richard Close lowered the firm's price target on Doximity to $48 from $58 and keeps a Hold rating on the shares. The firm updated its model to reflect an uncertain healthcare spending environment.
KeyBanc
Overweight
downgrade
$75 -> $60
2026-01-08
Reason
KeyBanc
Price Target
$75 -> $60
2026-01-08
downgrade
Overweight
Reason
KeyBanc lowered the firm's price target on Doximity to $60 from $75 and keeps an Overweight rating on the shares. Coming off a choppy year for HCIT stocks, fundamentally, the firm did see a "year of inflection" for many of its names with estimate revisions plus valuations largely bottoming. While KeyBanc expects momentum to continue for most of its coverage, the firm does see valuation multiples impacted by competition concerns and regulatory impacts.
About DOCS
Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
